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We isolated serologically identical (by serovar determination and porin variable region [VR] typing) strains
of Neisseria gonorrhoeae from an infected male and two of his monogamous female sex partners. One strain
(termed 398078) expressed the L1 (Gal13 3Gal13 4Glc13 4HepI) lipooligosaccharide (LOS) structure
exclusively; the other (termed 398079) expressed the lacto-N-neotetraose (LNT; Gal1 3 4GlcNAc1 3
3Gal1 3 4Glc1 3 4HepI) LOS structure. The strain from the male index case expressed both glycoforms
and exhibited both immunotypes. Nuclear magnetic resonance analysis revealed that sialic acid linked to the
terminal Gal of L1 LOS via an 23 6 linkage and, as expected, to the terminal Gal of LNT LOS via an 2 3
3 linkage. Insertional inactivation of the sialyltransferase gene (known to sialylate LNT LOS) abrogated both
L1 LOS sialylation and LNT LOS sialylation, suggesting a bifunctional nature of this enzyme in gonococci.
Akin to our previous observations, sialylation of the LNT LOS of strain 398079 enhanced the binding of the
complement regulatory molecule, factor H. Rather surprisingly, factor H did not bind to sialylated strain
398078. LOS sialylation conferred the LNT LOS-bearing strain complete (100%) resistance to killing by even
50% nonimmune normal human serum (NHS), whereas sialylation of L1 LOS conferred resistance only to 10%
NHS. The ability of gonococcal sialylated LNT to bind factor H confers high-level serum resistance, which is
not seen with sialylated L1 LOS. Thus, serum resistance mediated by sialylation of gonococcal L1 and LNT
LOS occurs by different mechanisms, and specificity of factor H binding to sialylated gonococci is restricted to
the LNT LOS species.
The lacto-N-neotetraose (LNT) lipooligosaccharide (LOS)
of Neisseria gonorrhoeae can become sialylated when grown
in medium supplemented with 5-cytidinemonophospho-N-
acetylneuraminic acid (CMP-NANA) (20). LOS sialylation
renders strains that are otherwise susceptible to complement-
mediated killing, resistant to killing by nonimmune normal
human serum (NHS) (26, 31). One explanation is the ability of
gonococci bearing the sialylated LNT LOS to bind factor H
(37), an important fluid-phase regulatory protein of the alter-
native pathway of complement (9, 29, 53, 56). Gonococcal LOS
undergoes significant phase variability in vivo, which may result
in a shift of expression away from the “conventional” (terminal
lactosamine of LNT) sialylation site (3, 12). LOS phase varia-
tion that results in the loss of the ability of an otherwise
serum-sensitive gonococcal strain to sialylate its LOS may ren-
der such a strain highly susceptible to complement-mediated
killing and therefore may be disadvantageous to an organism,
necessitating a redundant strategy to evade killing by comple-
ment. The terminal Gal on meningococcal L1 LOS (Gal13
3Gal1 3 4Glc1 3 4HepI) can also be sialylated (51). The
HepI hexose substitution of L1 LOS is structurally identical to
the PK blood group antigen (19) and is commonly found in the
LOS of Haemophilus and Moraxella spp. (5, 21, 48). Preserving
the ability to express L1 LOS may enable N. gonorrhoeae that
has lost the ability to express the LNT LOS to retain the ability
to sialylate LOS at an alternative site.
The interaction of the complement system (and in particu-
lar, regulatory molecules such as factor H) with sialylated L1
LOS has never been studied. The identification of four strains
of N. gonorrhoeae isolated from four different sexual partners
of a single index case, that were found to be identical by
serotyping but different in their LOS structure (the strains
expressed either the LNT LOS, the L1 LOS, or both), provided
us a unique opportunity to compare complement regulatory
events mediated by sialic acid in the context of the two LOS
immunotypes. In this study, we show that sialylation of only the
LNT LOS species, but not the L1 LOS, results in enhanced
binding of the alternative pathway regulatory molecule, factor
H. We also show that the LOS sialyltransferase elaborated
by gonococci is “bifunctional” in nature (i.e., capable of add-
ing sialic acid via two distinct linkages to LNT and L1 LOS
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eases, Evans Biomedical Research Center, Boston University Medical
Center, Room 627, 650 Albany Street, Boston, MA 02118. Phone:
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species). Sequence differences between gonococcal and bifunc-
tional meningococcal sialyltransferases are detailed.
MATERIALS AND METHODS
Bacterial strains and growth. N. gonorrhoeae strain 398 was isolated from a
male index case, and four additional strains (termed 398078 to 398081) were
obtained from four of his female sex contacts. Strain 1291b is a mutant derivative
of strain 1291 described previously (15), which had been selected under pyocin
pressure and expresses L1 LOS. Bacteria were grown in standard gonococcal
liquid medium supplemented with IsoVitaleX equivalent. In order to sialylate
LOS, CMP-NANA (Sigma Chemical Corporation, St. Louis, MO) was added to
growth media (concentration specified for each experiment).
In addition to the strains indicated above, N. gonorrhoeae strains F62 (40),
FA1090 (54), 24-1 (6), WG (28), and 179008, 255034, 269041, 374073, 339063,
256036, 274045, and 252035 (36) were used for sequence analysis of the LOS
sialyltransferase (lst).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot-
ting for LOS visualization and immunochemical characterization. Bacteria were
digested with proteinase K (Sigma), and lysates were treated with NuPAGE LDS
sample buffer (Invitrogen Life Technologies, Carlsbad, CA) and resolved on
12% Bis-Tris NuPAGE gels (Invitrogen) using MES (morpholineethanesulfonic
acid) running buffer, according to the manufacturer’s instructions. LOS was
visualized using a silver staining kit (Bio-Rad Laboratories, Hercules, CA). In
some experiments, LOS was transferred to polyvinylidene difluoride membranes
(Millipore) by Western blotting and probed with monoclonal antibodies (MAbs)
3F11 (2) and L1 (42) for immunochemical characterization of LOS.
LOS purification and analytical techniques. To sialylate LOS, bacteria were
grown in 2 liters of gonococcal liquid medium supplemented with IsoVitaleX
equivalent (1% [vol/vol]) and CMP-NANA (10 g/ml). Bacteria were harvested,
and LOS was purified by the hot water-phenol extraction method (55). Sugars
were determined as their alditol acetate derivatives by gas-liquid chromato-
graphy–mass spectrometry, and methylation analysis was carried out by the
NaOH-dimethy sulfoxide-methyl iodide procedure and analyzed by gas-liquid
chromatography–mass spectrometry as described previously (25). LOS was de-
O-acylated with anhydrous hydrazine to yield LOS-OH and examined by capil-
lary electrophoresis-electrospray mass spectroscopy as described previously (25).
Nuclear magnetic resonance (NMR) experiments were acquired on a Varian
Inova 400-MHz spectrometer using a 5-mm triple-resonance (1H, 13C, 31P)
probe. The lyophilized sugar sample was dissolved in 600 l of 99% D2O with
deuterated sodium dodecyl sulfate (10 mg/ml), and EDTA (1 mg/ml) was added
to improve the resolution of the spectrum. The experiments were performed at
25°C with suppression of the HOD (deuterated H2O) signal at 4.78 ppm. The
methyl resonance of acetone was used as an internal reference at 2.225 ppm for
1H spectra and 31.07 ppm for 13C spectra. Standard homo- and heteronuclear
correlated two-dimensional pulse sequences from Varian, correlation spectros-
copy, total correlated spectroscopy, nuclear Overhauser effect spectroscopy,
and 13C-1H heteronuclear single quantum correlation were used for general
assignments.
Construction of lst mutants. lst was amplified from chromosomal DNA pre-
pared from strain 398078 using a modification of primers SIALM-5F and
SIALM-16R (11), to incorporate PstI and HindIII restriction sites in the forward
and reverse primers, respectively: primer Lst-F (5AAAACTGCAGTTCAATTT
GTCGGAATGGAGTTTTAGG 3; PstI site in boldface) and primer Lst-R
(5CCCAAGCTTCTCATTAATTTTTATCGTCAAATGTCAAAATC 3; HindIII
site in boldface). PCR was carried out by denaturation at 94°C for 1 min,
annealing at 58°C for 1 min, and extension at 72°C for 2 min for 30 cycles. The
PCR product was digested with PstI and HindIII, gel purified using the
QIAquick gel extraction kit (QIAGEN), and cloned into plasmid pUC18 (In-
vitrogen; GenBank accession number L09136) (27) that had been digested with
the same enzymes, to yield plasmid pUC18-lst. The kanamycin resistance marker
was amplified by PCR from pUC4K (GenBank accession no. X06404; GE
Healthcare [formerly Amersham Biosciences], Piscataway, NJ) using primers
5 CCCGGCCGGGGGATCCGTCGACCTGCAG 3 and 5 CCCGGCCGG
CCCCGGATCCGTCGACCTGC 3 (introduced EagI sites indicated in bold-
face), digested with EagI, and cloned into a unique EagI restriction site at
nucleotide 672 of the lst in pUC18-lst, to yield a plasmid designated pUC18-
lst-Km containing insertionally inactivated lst. Gonococcal strains 398078 and
398079 were transformed with 1 g pUC18-lst-Km by previously described meth-
ods (4), and transformants were selected on GCB agar plates supplemented with
100 g/ml kanamycin. Insertional inactivation of lst was confirmed by PCR using
primers lst-F and lst-R, which yielded the expected 2.4-kb product. We also
amplified and sequenced the 5-kb region surrounding lst in strains 398, 398078,
and 398079 using primers based on the FA1090 genome sequence (GenBank
accession no. AE004969). The genetic organization in all of these strains was
identical to that of strain FA1090 and indicates that lst is monocistronic.
lst sequencing. Several isolated colonies from an overnight growth of N. gon-
orrhoeae on chocolate agar plates were suspended in 100 l double-distilled
water and heated to 90°C for 10 min. lst was amplified from the lysate (for-
ward primer 5-GGACACTCGGGGCGTATGTTCAA-3 and reverse primer
5-ATCCTGCCACGACAGTTTCCGC-3), and the resultant PCR product was
purified (Qiaquick) and sequenced (Tufts University Core Facility; http://www
.tucf.org/index.html) using the internal primers 5-TCAGCGGTGCGGTGT
TGACGATG-3 and 5-TACTTACTCCGCCATTTTCTATTT-3. DNA se-
quences were assembled using SeqMan (DNASTAR, Inc.) (45), and open read-
ing frames were identified using Gene Construction Kit 2 (Textco BioSoftware,
Inc., West Lebanon, NH). Translated lst sequences were aligned using ClustalW
(http://clustalw.genome.jp/) (47), and the alignments were analyzed using SeqVu
(http://www.imtech.res.in/pub/mmbm/seqvu/).
Sera and complement reagents. Sera obtained fresh from 11 healthy adults
who had no history of neisserial infection were pooled and stored at 80°C until
used. Purified factor H was purchased from Advanced Research Technologies
(San Diego, CA).
Antibodies. Anti-LOS MAb 3F11 (2) was provided by Michael A. Apicella,
University of Iowa, Iowa City, and MAb L1 (13) was provided by Wendell
Zollinger, Walter Reed Army Institute, Washington, D.C. Factor H that bound
to bacterial surfaces was detected by flow cytometry using affinity-purified goat
anti-human factor H at a concentration of 10 g/ml (kind gift of Michael
K. Pangburn, University of Texas Health Sciences Center, Tyler), and disclosed
using fluorescein isothiocyanate-conjugated anti-goat immunoglobulin G (Sigma) at
a dilution of 1:50.
Flow cytometry. Factor H bound to the bacterial surface was quantified by
flow cytometry using a Becton Dickinson FACScan cytometer, as described
previously (37).
Bactericidal assays. Serum bactericidal testing was performed as described
previously (23). Briefly2,000 CFU of bacteria grown to the mid-log phase were
incubated with NHS (concentration of NHS specified for each experiment) in a
final reaction mixture volume of 150 l. Duplicate aliquots of 25 l were inoc-
ulated onto chocolate agar plates at 0 and 30 min. Survival was calculated as the
percentage of the number of colonies that survived at 30 min relative to the
baseline colony counts at 0 min.
Nucleotide sequence accession numbers. The lst sequences have been submit-
ted to GenBank under accession numbers AY953446 to AY953459.
RESULTS
Identification of epidemiologically related gonococcal strains
bearing two different LOS sialylation sites and immunochemi-
cal characterization of LOS. Previously we have screened sev-
eral strains of N. gonorrhoeae that were sensitive to the bacte-
ricidal action of 10% NHS in the native state but became
serum resistant upon growth in media supplemented with
CMP-NANA (22). We examined these strains initially by
Western blotting for expression of the LNT LOS species (MAb
3F11 reactive) in the unsialylated state to identify 3F11-nega-
tive strains (i.e., strains that could become serum resistant
upon sialylation, but lacked the well-characterized LNT LOS
acceptor site). Using Western blotting with MAb 3F11 as the
probe, we identified one such strain, 398078, isolated from a
female contact of an index male with uncomplicated gonococ-
cal infection (infected with strain 398). Three additional fe-
male sex partners were infected with strains 398079, 398080,
and 398081. The five strains belonged to the Por1B-32 serovar
(17) and were also identical by Por variable region (VR) typing
(Por VR type B2,2,nt,1,3) (46), but showed dissimilar LOS
migration patterns on sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and varied with respect to MAb 3F11 bind-
ing. Prior studies have shown that the L1 LOS in N. meningi-
tidis can be sialylated (51), and thus we hypothesized that the
sialylatable non-3F11 LOS species in strain 398078 was likely
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to be L1 LOS (Gal13 3Gal13 4Glc13 4HepI). Strain
398 expressed two distinct LOS species (Fig. 1A) and was
found to react with both MAb 3F11 and a second MAb, L1,
specific for the L1 LOS type that also defines the PK blood
group antigen (19) (Fig. 1B), Strain 398078 expressed only the
lower-Mr LOS species and reacted with MAb L1, while isolate
398079 expressed only the higher-Mr LOS species, as seen on
silver stain that reacted with 3F11 (Fig. 1A and B), and weak
reactivity with MAb L1 by Western blotting (no corresponding
band seen on silver stain).
Strains 398080 and 398081 had LOS migration patterns sim-
ilar to those of the three strains examined (Fig. 1) and were not
studied further. As seen in Fig. 1A, both LOS species migrated
with slower velocities when strains were grown in media sup-
plemented with CMP-NANA, suggesting that a sialic acid res-
idue was added to both LOS species. Also shown in Fig. 1A are
the migration patterns of the LOS sialyltransferase (lst) dele-
tion mutants in the native (unsialylated) state and when grown
in the presence of CMP-NANA (discussed in detail below).
Collectively, these data suggested that the lower-Mr LOS spe-
cies that could be sialylated was similar to the L1 LOS of N.
meningitidis, and this was confirmed by mass spectrometry
analysis (see below).
Mass spectrometric analysis of the LOS of strain 398078,
and characterization of the nature of the sialic acid linkage.
The MS spectra of LOS-OH isolated from strains 398, 398078,
398078-NANA, 398079, 398079-NANA and a control strain,
1291b-NANA, were determined. As summarized in Table 1, it
can be seen that 398078 LOS-OH elaborated only the L1-like
extension, as evidenced by a single HexNAc known to be sub-
stituted on the distal HepII residue and three hexoses which
comprise the Gal1 3 3Gal1 3 4Glc1 3 extension from
HepI, whereas 398079 LOS-OH elaborated only the 3F11-like
(Gal1 3 4GlcNAc1 3 3Gal1 3 4Glc1 3) extension
from HepI plus another HexNAc known to be substituted on
the distal HepII residue. Strain 398 expressed both the L1- and
3F11-like extensions. It is worth noting that the epidemiolog-
ically linked strains (398, 398078, and 398079) display two
FIG. 1. Effects of sialylation on LOS migration of wild-type strains
and sialyltransferase (lst) mutants. Proteinase K-digested bacterial lysates
were resolved on a 12% Bis-Tris gel using MES running buffer, and LOS
was visualized by silver staining (A) and Western blotting (B). Strain 398
expressed both the 3F11 (4.5 kDa) and L1 (a lower-molecular-mass LOS
species) epitopes. Strain 398079 expressed predominantly the 3F11 LOS
species, while 398078 expressed only the L1 LOS. In all cases, migration
of the 3F11 and L1 LOS species was retarded upon growth in CMP-
NANA-containing media. Inactivation of lst resulted in loss of the ability
of all strains to sialylate either LOS species.
TABLE 1. Negative-ion MS data and proposed compositions of O-deacylated LPS from N. gonorrhoeae strains 398-NANA,









Observed Calculated Lipid Ab Core OS
398-NANA 903.3 2,712.3 2,712.4 1.0 952 1,761 3Hex, HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
1,000.3 3,004.1 3,003.4 0.5 952 2,052 Sial, 3Hex, HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
971.0 2,916.2 2,915.6 0.2 952 1,964 3Hex, 2HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
1,068.3 3,207.9 3,206.6 trace 952 2,255 Sial, 3Hex, 2HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
398078-NANA 903.3 2,712.1 2,712.4 1.0 952 1,761 3Hex, HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
1,000.4 3,004.3 3,003.4 0.5 952 2,052 Sial, 3Hex, HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
398079-NANA 971.3 2,916.9 2,915.6 1.0 952 1,967 3Hex, 2HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
1,068.8 3,209.4 3,206.6 0.4 952 2,257 Sial, 3Hex, 2HexNAc, 2Hep, 2Kdo, 2PEtn, lipid A-OH
1291b-NANA 862.3 2,589.9 2,589.4 1.0 952 1,641 3Hex, HexNAc, 2Hep, 2Kdo, PEtn, lipid A-OH
959.8 2,882.4 2,880.4 0.5 952 1,932 Sial, 3Hex, HexNAc, 2Hep, 2Kdo, PEtn, lipid A-OH
a Average mass units were used for calculation of molecular mass based on proposed composition as follows: Sial, 291.00; Hex, 162.15; Hep, 192.17; HexNAc, 203.19;
PEtn, 123.05; Kdo, 220.18. The average molecular weight of the O-deacylated lipid A (lipid A-OH) is as indicated. Relative intensity is expressed as relative to the
largest peak.
b As determined by MS-MS analyses.
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phosphoethanolamine (PEtn) molecules in their core OS, and
both of these PEtn moieties were localized to the distal hep-
tose residue by NMR studies (HepII) of the inner core OS
(data not shown). Control strain 1291b only elaborates one
PEtn residue in the core OS also located at the HepII sugar
(data not shown). 1291b also exhibits the L1-like extension. In
order to elucidate the position of the sialic acid linkage in these
strains, two approaches were adopted. For strain 398078-
NANA, methylation analysis revealed the presence of 6-linked
galactose residues, the amount being consistent with the level
of sialylation in the molecule. Strain 1291b-NANA was also
shown to elaborate sialic acid attached to the 6-position of a
galactose residue by NMR methods, whereby the inter-nuclear
Overhauser effect connectivities from the equatorial proton of
the sialic acid residue identified signals for the 6-position of
galactose as observed previously for N. meningitidis L1 LOS
(51). Finally, strain 398079-NANA was shown to elaborate
sialic acid at the 3-position of a galactose residue by virtue of
inter-nuclear Overhauser effect connectivities from the equa-
torial proton of the sialic acid residue that identified a signal
for the 3-position of galactose as observed previously for
N. meningitidis L3 LOS (32).
As detailed above, strains 398078 and 1291b differed in their
PEtn substitutions on HepII; the former strain had PEtn si-
multaneously at the 3- and 6-positions, while the latter had
only a 3-PEtn. Therefore, these data suggest that PEtn substi-
tutions on HepII did not influence the nature of the linkage of
sialic acid to LOS.
Interruption of lst results in the loss of the ability of gono-
coccal L1 LOS to sialylate. To determine if the well-charac-
terized lipooligosaccharide transferase, lst, was responsible for
sialylation of the L1 LOS in gonococci, we constructed mutants
using strains 398, 398078, and 398079 in which lst was inter-
rupted. The LOS migration patterns of the lst mutants in the
native (unsialylated) state and when grown in media supple-
mented with 100 g/ml CMP-NANA are shown in Fig. 1A
(lanes lst and lst-N, respectively). As expected, interruption of
lst in 398079 (expresses predominantly the 3F11-like LOS)
abrogated LOS sialylation in media containing CMP-NANA
(Fig. 1A, upper panel, lane marked lst-N). Insertional inacti-
vation of the same lst in 398078 resulted in loss of sialylated L1
LOS upon growth in CMP-NANA-containing media (Fig. 1A,
lower panel, lane marked lst-N). The 398 lst mutant lacked the
ability to sialylate both LOS glycoforms. Collectively, these
data examined together with the mass spectrometric analysis
strongly suggest that this lst in gonoccci (i.e., one that is known
to sialylate the LNT LOS [via an (2,3) linkage] also mediates
transfer of a sialic acid residue onto the terminal Gal in L1
LOS [via an (2,6) linkage], thereby rendering it a bifunctional
sialyltransferase.
Comparison of meningococcal and gonococcal lst gene prod-
ucts. Our data suggest that the gonococcal Lst is a bifunctional
enzyme capable of adding an (2,3)-linked sialic acid onto
LNT LOS and an (2,6)-linked sialic acid onto L1 LOS.
Wakarchuk et al. have shown that Lst from meningococcal
strain 126E is also a bifunctional enzyme with similar substrate
specificities (51). An isoleucine (Ile) residue at position 168
was found to be critical for bifunctionality of the 126E Lst.
Alignment of gonococcal strain FA1090 Lst (GenBank acces-
sion no. AE004969) with 126E Lst revealed an asparagine (Asn)
residue at amino acid position 168 in FA1090. Wakarchuk et al.
demonstrated by site-directed mutagenesis that an Asn at
position 168 of the MC58 Lst resulted in a protein with only
about 25% of the  (2,6) sialytransferase activity of an Lst with
an Ile at the same position (52). It is worth noting that the
FA1090 Lst also contained 7 additional amino acids at the
C-terminal end due to a T-to-C substitution at the site of
the 126E TAA stop codon.
To further examine gonococcal Lst sequence variation, we
amplified and sequenced lst from 14 gonococcal strains
(including FA1090). The region sequenced encompassed
the putative 7-amino-acid C-terminal extension found in
FA1090. These sequences were aligned with six meningo-
coccal Lst sequences available in GenBank (accession
numbers U60662 through U60664 and NMB0922) using
ClustalW. A representative alignment is shown in Fig. 2. We
identified 21 amino acid positions that diverged between
gonococci and meningococci. Within meningococci, Lst var-
ied at 11 amino acid positions with a maximal diversity of
3%. The 7 C-terminal amino acids found in FA1090 were
not observed in any meningococcal sequences. Among
gonococcal strains, the Lst sequences diverged at 7 amino
acids. The maximum difference noted between any two
sequences was 4 amino acids. This implies at least a 98.97%
homology in the Lst amino acid sequences among the strains
we examined. In every gonococcal strain sequenced, includ-
ing that from strain 398078, an Asn residue was noted at
FIG. 2. Lst sequences from 6 meningococcal and 14 gonococcal
strains were aligned using ClustalW. A representative alignment of the
bifunctional Lsts from meningococcal strain 126E and gonococcal
strain 398078 is shown. Species-specific variation occurred at 21 sep-
arate amino acid positions (boxed) distributed across the protein.
Strain variation within a species (shaded) was noted at 11 meningo-
coccal (above) and 7 gonococcal (below) amino acid positions. The
isoleucine (Ile) residue at position 168, shown to be critical for bifunc-
tionality of 126E Lst, is marked with an asterisk.
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position 168. All gonococcal lst genes contained the 7 addi-
tional amino acids first noted in FA1090.
Sialylation of the L1 LOS in N. gonorrhoeae does not en-
hance factor H binding. Sialylation of serum-sensitive gono-
coccal strains bearing the 3F11 LOS has been shown to en-
hance factor H binding and mediate serum resistance (37). We
examined factor H binding to strains 398, 398079 (LNT LOS),
and 398078 (L1 LOS) and their sialylated derivatives grown in
media containing 0, 1, 10, or 100 g/ml CMP-NANA) by flow
cytometry (histogram for 10 g/ml CMP-NANA has been
omitted to simplify the illustration). We observed that factor H
binding was enhanced only when 3F11 LOS-bearing strains 398
and 398079, but not strain 398078 (L1 LOS), was sialylated
(Fig. 3, upper panel). Maximal factor H binding was seen even
at 1 g/ml CMP-NANA and was similar to binding observed
with 100 g/ml CMP-NANA. The lst mutant derivatives of these
strains did not bind factor H when grown in CMP-NANA-con-
taining media (Fig. 3, lower panel). These data suggest that en-
hancement of factor H binding to sialylated gonococci is re-
stricted to strains that bear the LNT LOS species; enhancement
was not seen in the strain that expressed only L1 LOS.
The above data show that levels of factor H binding to the
LNT LOS-bearing strains were similar over CMP-NANA con-
centrations ranging from 1 to 100 g/ml. We next quantified
the proportion of LOS of strains 398078 (L1) and 398079
(mostly 3F11) that was sialylated at the different CMP-NANA
concentrations to ensure that differences in the level of sialy-
lation between the two LOS species did not account for the
inability of sialylated L1 LOS to bind to factor H. Direct mass
spectrometry showed that 5%, 25%, and 30% of glycoforms
were sialylated when strain 398079 was grown in 1, 10, and
100 g/ml CMP-NANA, respectively. The corresponding per-
centage of sialylated glycoforms in strain 398078 grown in the
three concentrations of CMP-NANA (in order of increasing
concentration) were 10%, 40%, and 55%, respectively. In a
separate experiment, we repeated the sialic acid estimation in
samples grown in 1 and 10 g/ml of CMP-NANA using pre-
cursor ion scanning for the m/z 951 species, which represents
the basic O-deacylated lipid A structure without additional
phosphorylation. The percentages of 398079 LOS (predomi-
nantly 3F11) that was sialylated were 30% and 50%, and the
percentages of sialylated L1 LOS in 398078 were 15 and 62.5
when organisms were grown in 1 and 10 g/ml CMP-NANA,
respectively. These data show that the two glycoforms were
sialylated to similar extents and that only a small proportion of
LOS sialylation was necessary for maximal factor H binding to
the strain bearing the LNT LOS. Proportionally higher sialy-
lation of L1 LOS did not result in factor H binding.
Differences in the efficiency of serum resistance conferred by
sialylation of the 3F11 and L1 LOS. We examined the ability
of strains 398079 (LNT LOS) and 398078 (L1 LOS) to resist
the bactericidal action of 10% NHS when grown in media con-
taining increasing concentrations of CMP-NANA. Figure 4A
shows that LNT LOS-expressing strain 398079 demonstrated
88% survival when grown in media containing 1 g/ml CMP-
NANA, while MAb L1-positive strain 398078 showed only
17% survival under similar growth conditions. Survival of
398078 gradually increased with increasing CMP-NANA con-
centrations in the media. Strain 398, which expressed both
LOS species, showed an intermediate level of serum resistance.
The lst mutants of all three strains were completely killed in
FIG. 3. Factor H binds only to gonococcal strains (398 and 398079) bearing sialylated lacto-N-neotetraose (3F11) LOS, but not to strain 398078
bearing sialylated L1 LOS. (Upper panel) Factor H binding to strains 398 (LNT and L1 LOS), 398078 (L1 LOS), and 398079 (LNT LOS) grown either
without CMP-NANA (histogram represented by thin solid line) or in media containing 1 g/ml (bold line) or 100 g/ml (gray shaded histogram)
CMP-NANA was quantified by flow cytometry. (Lower panel) Factor H binding to lst mutants of 398, 398078, and 398079 grown with (100 g/ml; gray
shaded histogram) or without CMP-NANA. The x axis represents fluorescence, and the y axis denotes the number of events. Isotype controls (antibodies
alone, no factor H) are shown in each plot by thin broken lines. One representative experiment of duplicate experiments is shown.
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even 10% NHS when grown in media containing CMP-NANA
at 100 g/ml (data not shown).
In a separate experiment (Fig. 4B), we examined the
degree of serum resistance that was conferred by sialylation
of the two LOS species. LOS was fully sialylated by growth
in media containing 100 g/ml CMP-NANA, and bacteria
were subjected to the effects of 10%, 25%, and 50% NHS in
a serum bactericidal assay. We observed that sialylation of
398 and 398079 resulted in a higher degree of serum resis-
tance (both strains fully resisted even 50% NHS), compared
to sialylated 398078, which fully resisted only 10%, but
was killed 75% and 99.5% in 25% and 50% NHS, respec-
tively.
DISCUSSION
In order to survive the milieu of the genital tract and estab-
lish infection, N. gonorrhoeae must evade the innate immune
system at the level of the genital mucosa. Naturally occurring
antibody and complement are important effector arms of the
immune response at the cervical mucosal level (33). Gonococ-
cal LOS undergoes considerable phase variation in vivo (3, 12,
41), which could be advantageous in evading complement-
mediated killing. For example, alteration in LOS structure may
decrease binding of preexisting natural anti-LOS antibody to
the bacterial surface. However, this could occur at the expense
of the loss of a mechanism to evade complement.
Gonococci have developed a variety of mechanisms to evade
complement-mediated killing. Sialylation of the lacto-N-neote-
traose LOS of otherwise serum sensitive strains renders them
resistant to bactericidal killing by NHS (31). This is termed
“unstable” serum resistance, because it is a property that is lost
when organisms are subcultured onto media that lack the
donor molecule for sialic acid, CMP-NANA (30). Certain
gonococcal strains are intrinsically resistant to killing by NHS,
independent of LOS sialylation, a property termed “stable”
serum resistance (38, 39). Stable serum resistance may in part
be mediated by the ability of gonococcal porin to bind com-
plement regulatory molecules such as factor H and/or C4b-
binding protein (C4bp) (35, 36).
Prior work in our laboratory has shown that sialylation of
gonococcal 3F11 (LNT) LOS enhances factor H binding,
which results in regulation of the alternative pathway of com-
plement (37). Factor H is a key soluble phase regulator of the
alternative pathway of complement and acts as a cofactor in
the factor I-mediated cleavage of C3b to the hemolytically
inactive molecule, iC3b (29, 44, 56). Factor H also limits the
amount of C3b deposited on the bacterial surface by virtue of
its decay accelerating function, in which the factor Bb is irre-
versibly dissociated from C3-convertase, C3b,Bb (10, 29, 44,
53, 56).
NMR analysis of the sialylated LOS of 398078 showed an
(2,6)-linked sialic acid residue to the terminal Gal on HepI.
This contrasted with the sialylation observed on the serologi-
cally identical and epidemiologically related strain, 398079
(LNT LOS), which as expected, possessed an (2,3)-linked
sialic acid. Inactivation of lst in 398078 and 398079 resulted in
an inability of both strains to sialylate their LOS and suggests
that the same Lst enzyme was capable of adding sialic acid in
two distinct configurations on two different glycoforms. Bifunc-
tionality of Lst has previously been described in meningococcal
strain 126E. The presence of an Ile residue at position 168 of
the 126E Lst was deemed critical for the ability to sialylate the
L1 LOS at the 6-position. A comparison of the amino acid
sequences of the Lst proteins of 398078 and 126E showed that
the former had an Asn, but not an Ile residue at position 168.
All gonococcal lsts that we sequenced encoded Asn at position
168. Another noteworthy feature of the gonococcal Lst was the
presence of 7 additional C-terminal amino acids that were not
seen in the meningococcal enzyme. Our data suggest that the
molecular basis for bifunctionality of gonococcal Lst may
differ from that reported for meningococci. The amino
acid(s) that impart gonococcal Lst bifunctionality remains to
be determined.
FIG. 4. (A) Serum resistance conferred by sialylation of LNT
LOS occurs at lower CMP-NANA concentrations compared to L1
LOS sialylation. Bacteria were grown in the presence of increasing
concentrations of CMP-NANA, and serum bactericidal assays were
performed in the presence of 10% NHS. Strain 398079 showed 88%
survival when grown in the presence of 1 g/ml CMP-NANA, while
398078 showed only 17% survival under similar growth conditions.
A gradual increase in serum resistance was seen with 398078 as
CMP-NANA concentrations were increased. The mean (standard
deviation) of one representative experiment performed in duplicate
is shown. (B) Sialylation of lacto-N-neotetraose LOS confers a
higher level of serum resistance than sialylation of L1 LOS. Strains
398, 398078, and 398079 were grown in media containing 100 g/ml
CMP-NANA in an attempt to maximize LOS sialylation. Bacteria
were then subjected to serum bactericidal testing in the presence of
increasing serum concentrations. The mean (standard deviation)
of one representative experiment performed in duplicate is shown.
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Meningococci that cause invasive disease are encapsulated,
and LOS sialylation does not appear to impact virulence at
least in animal models and may play only a minor role in
meningococcal serum resistance (49, 50). In contrast, gono-
cocci may depend more on LOS sialylation to survive the
effects of complement, and this may be reflected in the main-
tenance of a relatively highly conserved and bifunctional en-
zyme among isolates. The Lst enzyme has recently been local-
ized to the bacterial outer membrane (43), but the kinetics of
the Lst enzymes of the two pathogenic neisserial species were
not compared in situ; likewise, the differences in sialylation
rates of the 3F11 and L1 LOS species are unknown.
We compared the abilities of strains bearing sialylated L1
LOS (NANA23 6Gal13 3Gal13 4Glc13 4HepI) and
predominantly sialylated 3F11 LOS (NANA23 3Gal13
4GlcNAc13 3Gal13 4Glc13 4HepI) to bind factor H.
As expected, the latter strain bound factor H well, but the
sialylated L1 LOS did not enhance factor H binding to the
gonococcal surface (Fig. 3). These data suggest that the bind-
ing of factor H to sialylated gonococci is highly specific and
restricted to strains that possess sialylated lacto-N-neotetraose
LOS. Specificity of factor H binding to polyanions is illustrated
by the observation that factor H binds to heparin, sialic acid,
dextran sulfate, chondroitin sulfate A, and type III and IV
carrageenan, while little or no binding occurs to colominic
acid, chondroitin sulfate C, keratan sulfate, hyaluronic acid, or
polyaspartic acid (24). Ongoing work in our laboratory has
shown that only sialylation of gonococcal, but not meningococ-
cal, LNT LOS augments factor H binding. Preliminary evi-
dence suggests that a cooperative mechanism between gono-
coccal porin and sialylated LNT LOS is required for factor H
binding in this neisserial species (18).
Factor H binding to strain 398079 was not augmented as the
proportion of sialylated LOS increased, possibly because the
bacterial surface has already been “saturated” with factor H.
Approximately 50,000 factor H molecules have been shown to
bind to a single group A streptococcus (14). The factor H
binding and serum bactericidal data obtained at lower CMP-
NANA concentrations are likely to be biologically relevant
because the amount of CMP-NANA obtained from cell lysates
from whole blood is 	1 g/ml (26). Shifting of serum-sensitive
N. gonorrhoeae to a serum-resistant phenotype was noticeable
when bacteria were grown in media containing as little as 2 

102 nM (0.01 g/ml) CMP-NANA (8).
Lipopolysaccharides of Actinobacillus actinomycetemcomi-
tans (57), Klebsiella pneumoniae (1), and Salmonella enterica
serovar Montevideo (16) have been shown to bind to C3b.
Edwards et al. have identified gonococcal LOS as a target
where C3b is converted to iC3b (7). Recently, we have identi-
fied N. meningitidis LOS as a target for complement C4b and
have shown that alterations in HepI hexose substitutions and
phosphoethanolamine residues on HepII can modulate the
nature of the linkage (i.e., amide versus ester) of C4b with LOS
(34). Sialylation of both 398078 and 398079 decreased C4 bind-
ing to a similar extent in a flow cytometry assay (data not
shown), suggesting that LOS sialylation may also diminish or
prevent C4b binding to LOS. The differences in the level
(or degree) of serum resistance between 398078 and 398079,
when grown in the presence of increasing concentrations of
CMP-NANA (Fig. 4A), reflect the importance of factor H
bound to sialylated LNT LOS on 398079 in down-regulating
complement. Therefore any alternative pathway amplification
that is initiated by the classical pathway is regulated by factor
H bound directly to 398079. On the other hand, 398078 must
rely on classical pathway regulation by obscuring targets for
C4b. Such a mechanism would likely require a greater propor-
tion of LOS to be sialylated and may be less efficient than a
mechanism that involves binding of a complement regulator
(in addition to obscuring targets for C3b and C4b).
In conclusion, we have demonstrated sialylation of the L1
(or PK-like) LOS in gonococci and defined the nature of the
sialic acid linkage. Although the chemistry of the sialylation of
gonococcal LOS is similar to that seen in meningococci, we
have noted differences in amino acid sequences of the bifunc-
tional Lst enzymes in these two neisserial species. Our obser-
vations suggest that the bifunctionality of gonococcal Lst is not
related to the Ile at position 168 as was reported in meningo-
cocci. Determining the requirements for the ability of gono-
coccal Lst to add sialic acid in two distinct configurations may
shed light on the structure-function relationships of this en-
zyme. The ability of gonococci to sialylate two distinct LOS
species would enable strains to undergo a phase variation of
LOS from L1 to LNT (or vice versa), while retaining the ability
to evade complement (albeit by different mechanisms). This
may be important for strains such as 398078, which do not bind
either factor H or other complement regulators such as C4bp
in the native (unsialylated) state.
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ERRATUM
Enhanced Factor H Binding to Sialylated Gonococci Is Restricted to the
Sialylated Lacto-N-Neotetraose Lipooligosaccharide Species:
Implications for Serum Resistance and Evidence for a
Bifunctional Lipooligosaccharide Sialyltransferase in Gonococci
Sunita Gulati, Andrew Cox, Lisa A. Lewis, Frank St. Michael, Jianjun Li, Ryan Boden, Sanjay Ram,
and Peter A. Rice
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School,
Worcester, Massachusetts 01605; National Research Council, Ottawa, ON K1A 0R6, Canada;
and Evans Biomedical Research Center, Boston University Medical Center,
Boston, Massachusetts 02118
Volume 73, no. 11, p. 7390–7397, 2005. Page 7390, abstract: “L1 (Gal133Gal134Glc134HepI)” should read “L1
(Gal134Gal134Glc134HepI).”
Column 2, lines 1 and 2: “L1 LOS (Gal133Gal134Glc134HepI)” should read “L1 LOS (Gal134Gal13
4Glc134HepI).”
Page 7392, column 2, line 1: “L1 LOS (Gal133Gal134Glc134HepI)” should read “L1 LOS (Gal134Gal13
4Glc134HepI).”
Column 2, line 7 from the bottom: “the Gal133Gal134Glc13 extension” should read “the Gal134Gal134Glc13
extension.”
Page 7396, column 1, lines 13 and 14: “L1 LOS (NANA236Gal133Gal134Glc134HepI)” should read “L1 LOS
(NANA236Gal134Gal134Glc134HepI).”
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